You are here:
Publication details
Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study
Authors | |
---|---|
Year of publication | 2015 |
Type | Article in Periodical |
Magazine / Source | American Journal of Hematology |
MU Faculty or unit | |
Citation | |
Web | http://onlinelibrary.wiley.com/doi/10.1002/ajh.23964/epdf |
Doi | http://dx.doi.org/10.1002/ajh.23964 |
Field | Oncology and hematology |
Keywords | HIGH-DOSE METHYLPREDNISOLONE; RITUXIMAB; COMBINATION; FLUDARABINE; IBRUTINIB; EFFICACY; THERAPY; CD20 |
Attached files | |
Description | The treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) remains a challenging clinical issue. An important treatment option is the use of high-dose corticosteroids. The purpose of this clinical trial was to determine the efficacy and toxicity of an ofatumumab-dexamethasone (O-Dex) combination in relapsed or refractory CLL. The trial was an open-label, multicenter, nonrandomized, Phase II study. The O-Dex regimen consisted of intravenous ofatumumab (Cycle 1: 300 mg on day 1, 2,000 mg on days 8, 15, and 22; Cycles 2-6: 1,000 mg on days 1, 8, 15, and 22) and oral dexamethasone (40 mg on days 1-4 and 15-18; Cycles 1-6). The O-Dex regimen was given until best response, or a maximum of six cycles. Thirty-three patients (pts) were recruited. Twenty-four (73%) pts completed at least three cycles of therapy. The remaining nine pts were prematurely discontinued owing to Grade 3/4 infections (seven pts), disease progression (one pt), or uncontrollable diabetes mellitus (one pt). Overall response rates/complete remissions (ORR/CR) were achieved in 22/5 pts (67/15%). The median progression-free survival (PFS) was 10 months. In pts with p53 defects (n=8), ORR/CR were achieved in 5/2 pts (63/25%) with a median PFS of 10.5 months. The median overall survival (OS) was 34 months. The Grades 3-5 infectious toxicity in 33% of pts represented the most frequent side effect during the treatment period. In conclusion, the O-Dex regimen shows a relatively high ORR and CR with promising findings for PFS and OS. The study was registered at (NCT01310101). Am. J. Hematol. 90:417-421, 2015. (c) 2015 Wiley Periodicals, Inc. |